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Abstract
Background: Peroxisome proliferator-activated receptor (PPAR) α, βδ and γ are nuclear
receptors activated by fatty acid metabolites. An anti-inflammatory role for these receptors in
airway inflammation has been suggested.
Methods: Nasal biopsies were obtained from 10 healthy volunteers and 10 patients with
symptomatic allergic rhinitis. Nasal polyps were obtained from 22 patients, before and after 4
weeks of local steroid treatment (fluticasone). Real-time RT-PCR was used for mRNA
quantification and immunohistochemistry for protein localization and quantification.
Results: mRNA expression of PPARα, PPARβδ, PPARγ was found in all specimens. No differences
in the expression of PPARs were obtained in nasal biopsies from patients with allergic rhinitis and
healthy volunteers. Nasal polyps exhibited lower levels of PPARα and PPARγ than normal nasal
mucosa and these levels were, for PPARγ, further reduced following steroid treatment. PPARγ
immunoreactivity was detected in the epithelium, but also found in smooth muscle of blood vessels,
glandular acini and inflammatory cells. Quantitative evaluation of the epithelial immunostaining
revealed no differences between nasal biopsies from patients with allergic rhinitis and healthy
volunteers. In polyps, the PPARγ immunoreactivity was lower than in nasal mucosa and further
decreased after steroid treatment.
Conclusion: The down-regulation of PPARγ, in nasal polyposis but not in turbinates during
symptomatic seasonal rhinitis, suggests that PPARγ might be of importance in long standing
inflammations.
Background
Seasonal allergic rhinitis is the result of an immunologi-
cally mediated hypersensitivity reaction of the nasal
mucosa, initiated by exposure to specific allergens. The
reaction is characterized by the infiltration of various
inflammatory cells, like eosinophils, neutrophils,
basophils, monocytes, and lymphocytes. When the sea-
son is over, symptoms and signs of inflammation disap-
pear and the nasal mucosa gradually returns to a situation
close to that in healthy non-allergic subjects [1-4]. Nasal
polyposis is another inflammatory disorder of the upper
airways and is, like allergic rhinitis, related to an infiltra-
tion of inflammatory cells [5]. The allergic inflammation
is driven by a network of pro-inflammatory cytokines [6]
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in nasal polyposis [7]. In addition, there is an emerging
concept that anti-inflammatory pathways affect the out-
come of inflammatory diseases, including those in the air-
ways [8]. Peroxisome proliferator-activated receptors
(PPARs) have been suggested to play such an anti-inflam-
matory role [9-11].
Peroxisome proliferator activated receptors (PPARs) are
DNA-binding nuclear hormone receptors that are up-reg-
ulated in response to high fat diets [12]. PPARs are struc-
turally related to the type II nuclear receptors, including
the thyroid hormone receptors and occur intracellularly
both in the cytosol and in the nucleus. Although today
there are no proven high-affinity pathways for endog-
enous ligands in-vivo, all PPARs are activated by fatty
acids. To date, three mammalian PPAR subtypes have
been identified, referred to as α, β or δ (here named βδ),
and γ, which are encoded by separate genes [13,14]. They
share a 60–80% homology in their binding domains and
have subtle differences in ligand specificity in that e.g.
eocosanoid products of the lipooxygenase pathway such
as leukotriene B4 and 8-S-hydroxytetraenoic acid (8-S-
HETE) activates PPARα [15], prostaglandin (PG) I2 acti-
vates PPARβδ and, 15-HETE and the PGD2 derivative, 15-
deoxy-∆12,14-PGJ2, activates PPARγ [16,17]. PPARs are
generally expressed at a high level in adipose tissue, and
play a prominent role in several physiological processes
including the control of lipid and lipoprotein metabo-
lism, and glucose homoeostasis [18]. PPARs might also be
involved in cardiovascular disease [19] and cancer [20]. A
role for PPARγ in allergic conditions as well as asthma has
been suggested, but remains controversial [21]. In murine
models of human asthma, it has been demonstrated that
local administration of PPARγ agonists decreases serum
levels of IgE, and have beneficial effects on airway hyper-
responsiveness and lung eosinophilia [22,23]. One study
of PPARγ in samples from inflamed human airways has
demonstrated that the immunoreactivity for PPARγ is aug-
mented in the bronchial submucosa, the airway epithe-
lium and the smooth muscle cells of asthmatics compared
to healthy subjects [24]. The increasing number of reports
describing an anti-inflammatory role for PPARs (espe-
cially PPARγ) in various disease models [9-11], have
prompted us to examine the expression and localization
of PPARs in allergic rhinitis and nasal polyposis using




The study included 10 patients (five women) with symp-
tomatic birch or grass pollen-induced allergic rhinitis and
10 healthy volunteers (four women), serving as controls.
The median age of the patients and controls was 36 (28–
50) years and 32 (22–46) years, respectively. In addition,
22 patients with bilateral nasal polyposis (four women)
were included before or after treatment with steroids
(median age 52 [22–79] years). In 7 of these patients, two
sets of polyps were obtained, one before and one after
steroid treatment (fluticasone, see below).
The diagnosis of birch and grass pollen induced allergic
rhinitis was based on a positive history of intermittent
allergic rhinitis and positive skin prick tests to birch and/
or timothy. Exclusion criterias included a history of peren-
nial symptoms, upper airway infection during the time of
visit, positive skin prick tests to house dust mite (Dermat-
ophagoides Pteronyssimus and D. Farinae) and molds
(Cladosporium and Alternaria), and treatment with local or
systemic corticosteroids during the last 2 months. Occa-
sional use of antihistamines was accepted. The controls
were all symptom-free, had no history of allergic rhinitis
and had negative skin prick tests to a panel of allergens
including birch, timothy, mugwort, house dust mite
horse, dog, cat and molds.
Nasal polyposis was identified on the basis of clinical
symptoms (nasal obstruction and anosmia) and the visu-
alization of polyps by anterior rhinoscopy. A complete
ear, nose-, and throat examination was performed before
inclusion. Patients with cystic fibrosis and ciliary dyski-
nesia were excluded from the study along with subjects
with a history of concurrent purulent nasal infection in
the six weeks before the study or any kind of nasal surgery
during the last year. None of the patients suffered from
asthma that required continuous medication.
All patients were recruited through physician referrals and
the healthy volunteers were recruited via advertisements
in the local press. The study was approved by the Ethics
Committee of the Medical Faculty, Lund University.
Study design for obtaining nasal biopsies
The patients were seen either during the birch (5 patients)
or during the grass pollen season (5 patients). They were
included when they had experienced substantial symp-
toms of rhinoconjunctivitis (itchy nose and eyes, sneez-
ing, nasal secretion and nasal blockage) during 3–5
consecutive days. All patients were seen within 5–10 days
after the first appearance of symptoms. A local pollen
count confirmed the presence of relevant pollen during
this period. During the visit patients were asked to evalu-
ate their nasal symptoms, itching/sneezing, secretion and
blockage, individually using an arbitrary scale from 0 to 3
(0 = no, 1 = mild, 2 = moderate, 3 = severe symptoms) A
total nasal symptom score was then calculated by addi-
tion of the three scores. Anterior rhinoscopy was per-
formed and oedema and secretion in each nostril were
scored from 0–2 (0 = no, 1 = mild, 2 = severe). TotalPage 2 of 8
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the scores for each sign from each nostril. All participants
had at least 6 in total symptom score and at least in 5 total
oedema/secretion score. The healthy volunteers were seen
during the same period.
Biopsies were taken from the inferior turbinate after topi-
cal application of local anesthesia containing lidocainhy-
drochloride-nafazoline for 20 minutes. The specimens for
mRNA extraction were immediately placed in RNA-later
(QIAGEN) and frozen. For immunohistochemistry, spec-
imens were immersed in an ice-cold fixative solution
composed of 2% formaldehyde and 0.2% picric acid,
buffered to pH 7.2 with 0.1 M phosphate buffer.
Study design for obtaining nasal polyps
Patients with nasal polyposis participated in the study
during the autumn/winter (outside the pollen season). In
patients supplying polyps before treatment all steroids
(systemic, inhaled and intranasal) were withheld during a
minimum of six weeks before the study (three patients
were steroid naïve). All patients supplying polyps after
treatment were seen by the surgeon and medication with
fluticasone, 200 µg twice a day initiated. After four weeks
on this course one set of polyps was removed. Polyps were
removed using topical application of local anesthesia con-
taining lidocainhydrochloride-nafazoline for about 20
minutes. In patients providing two sets of polyps a wash-
ing out period of two weeks were used after the first set
was removed and the Fluticasone medication started.
RNA extraction and RT-PCR
RNA was extracted from homogenized biopsies using the
RNeasy Mini Kit (QIAGEN GmbH), according to the sup-
plier's protocol including an optional DNaseI (Qiagen)
treatment. Total RNA quantity and quality were assessed
by a spectrophotometer and the wavelength absorption
ratio (260/280 nm) was between 1.8 and 2.0 in all prepa-
rations. Reverse transcription to cDNA was carried out
with Omniscript™ reverse transcriptase kit (QIAGEN
GmbH) with oligo-dT primer in a final volume of 20 µl
using the Mastercycler personal PCR machine (Eppendorf
AG, Germany), at 37°C for 1 h.
Quantitative real time-PCR
Quantitative real-time PCR assays were performed using
the Smartcyckler II detection system (Cephied, USA).
Intron over-spanning oligonucleotide primers for detec-
tion of PPARα, PPARβδ, PPARγ and β-actin were designed
using Primer Express® 2.0 software (Applied Biosystem,
USA) and synthesized by DNA Technology A/S (Aarhus,
Denmark, table 1). PCR was performed using QuantiTect
SYBR® Green RT-PCR kit (QIAGEN) in a final volume of
25 µl. Reactions were incubated at 95°C for 15 min, then
incubated 46 cycles at 94°C for 30 s followed by 55°C for
60 s (initially 65°C, followed by a 2°C decrease of the first
6 cycles). Standard curves for the PCR reactions were pre-
pared using half 10log dilutions of PCR product generated
from target cDNA. Specific PCR products were analysed by
running melting curve and visualized by agarose electro-
phoresis.
Gene expression changes were assessed using the compar-
ative cycle threshold (Ct) method http://docs.appliedbio
systems.com/pebiodocs/04303859.pdf. The relative
amounts of mRNA for PPARα, PPARβδ and PPARγ were
determined by subtracting Ct values for these genes from
the β-actin Ct value (housekeeping gene) and expressed as
the amount of mRNA in relation to 100,000 mRNA mol-
ecules of β-actin (100,000·2∆Ct).
Immunohistochemistry
The sections from nasal biopsies and nasal polyps were
processed for the immunocytochemial demonstration of
PPARγ. The PPARγ antibody (Cayman Chemical Com-
pany, Ann Arbor, Mi, USA) was raised in rabbit against a
peptide corresponding to amino acids 82–101 of human
PPARγ1. It cross-reacts with PPARγ2. The antibody was
used in dilution 1:800. For the demonstration of the anti-
gen-antibody reaction indirect immunofluorescence was
used. Briefly, the cryostat sections were first washed with
PBS and then rinsed in PBS for 15 min followed by incu-
bation for 45 min with secondary antibodies raised
against rabbit IgG and conjugated to FITC (1:80; swine
anti-rabbit FITC, DAKO, Copenhagen, Denmark). Slides
were cover-slipped in glycerol/PBS 2:1 (v/v) containing
Table 1: Intron over-spanning oligonucleotide primers
Target Accession nr Primer Sequence (5'-3')
PPARα NM005036 forward ACTCAACAGTTTGTGGCAAGACA
reverse GGAAGCACGTCCTCACATGA
PPARβδ NT007592 forward GCACATCTACAATGCCTACCTGAA
reverse CTCGATGTCGTGGATCACAAA
PPARγ NM005037 forward AAGTTCAATGCACTGGAATTAGATGA
reverse TGTAGCAGGTTGTCTTGAATGTCTTC
β-actin NM001101 forward GCCAACCGCGAGAAGATG
reverse ACGGCCAGAGGCGTACAGPage 3 of 8
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chromefluorescence filters.
Negative controls for non-specific binding included nor-
mal rabbit serum without primary antibody and second-
ary antibody alone. Since cross-reactions with other
proteins containing amino acid sequences recognized by
the antisera could not be excluded, it is appropriate to
refer to the immunoreactive material as "PPARγ-like". For
brevity, the immunoreactive material is referred to as
PPARγ in the text. For quantification, sections were ana-
lyzed with Visiopharm Integrator System® v2.1.2 (Visiop-
harm, Hørsholm, Denmark). The whole batch was
immunostained and processed at the same time and the
slides were analysed at the same time. Since the back-
ground level can differ between the specimens, each slide
was individually analysed in that the background level
was used as a reference to the induced immunostaining.
An intensity reaching a certain threshold was regarded as
positive and the area of this staining was measured in rela-
tion to the length of the epithelium. The computer pro-
gram does not analyse the intensity of the staining but
only staining that reached a certain level of intensity.
Statistical analysis
All data sets were analysed by Kolmogorov Smirnov test
and since the data for PCR expression predominantly not
was Gaussian distributed, Kruskal-Wallis test or Wilcoxon
signed rank test was performed and expressed as median
value (minimum-maximum), whereas the immunohisto-
chemistry data that were found Gaussian distributed were
analyzed by t-test and expressed as mean value ± s.e.m.
The null hypothesis was rejected at P < 0.05.
Results
The standard curves for PPARα, PPARβδ, PPARγ and β-
actin had correlation coefficients ranging between 0.93
and 0.99 and generated slope values not significantly dif-
ferent from each other. The efficiency of the PCR reaction
was calculated and ranged between 1.96 and 2.01. The RT-
PCR analysis of total RNA extracted from nasal biopsies
and nasal polyps demonstrated the presence of PPARα,
PPARβδ, PPARγ and β-actin in all samples. Melting curve
analysis revealed a single peak in each sample and agarose
electrophoresis generated expected PCR products with a
single band close to the 100 bp marker.
Of the three PPARs, the expression of PPARα and γ were
generally higher than the levels of PPARβδ. No differences
were obtained when expression levels for the different
PPARs in nasal biopsies from healthy volunteers were
compared with biopsies derived from patients with symp-
tomatic allergic rhinitis (Figure 1): PPARα (mRNA in rela-
tion to 100,000 mRNA molecules of β-actin) 170 (53–
4512) and 82 (43–491), PPARβδ 52 (14–481) and 43
(18–464) and PPARγ 305 (144–2628) and 321 (171–
699) in controls and patients with rhinitis, respectively.
All three PPARs were also detected in nasal polyps
obtained from patients not subjected to steroid treatment
(Figure 1). The mRNA levels for PPARα and PPARγ were
significantly lower in polyps than in normal nasal mucosa
(mRNA in relation to 100,000 mRNA molecules of β-
actin; 31 (12–232) and 132 (52–243) for PPARα and
PPARγ, respectively). No corresponding differences were
seen for and PPARβδ
In order to evaluate if local steroid treatment could affect
the expression of the different PPARs we managed to
obtain one set before and another set after treatment with
steroids from seven of the polyposis patients (Figure 2).
Four weeks of treatment resulted in a reduction in the
expression of PPARγ (mRNA in relation to 100,000
mRNA molecules of β-actin; 154 (87–244) before and 72
(50–111) after treatment). The expression of PPARα and
PPARβδ was not affected by steroid treatment.
Using immunohistochemistry the protein expression of
PPARγ was localized and evaluated (Figure 3A–D). In the
nose, PPARγ immunofluorescence was prominent in the
surface epithelium, but was also detected in smooth mus-
cle around blood vessels and in acini of small seromucous
glands. In addition, PPARγ immunofluorescence was seen
Expression levels of PPARα, PPARβδ and PPARγ in biopsies of th  nasal mucosa from 10 healthy volunteers (contr l) and 10 patients with symptomatic allergic rhi itis (allergic) togeth r with bi psies f nasal pol ps from 11 patients withbilateral n sal polyposis (polyp)Fi ure 1
Expression levels of PPARα, PPARβδ and PPARγ in biopsies 
of the nasal mucosa from 10 healthy volunteers (control) and 
10 patients with symptomatic allergic rhinitis (allergic) 
together with biopsies of nasal polyps from 11 patients with 
bilateral nasal polyposis (polyp). Levels of PPAR mRNA are 
calculated in relation to 100,000 mRNA molecules of β-actin. 
Bold lines represent the median values. The expression of 
PPARα and PPARγ was lower in polyps than in normal nasal 
mucosa (**p < 0.01).Page 4 of 8
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staining could be calculated between nasal biopsies
obtained from healthy controls and in biopsies derived
from patients with symptomatic allergic rhinitis. In pol-
yps, the PPARγ staining was most prominent in the basal
epithelial cells. Quantitative computerized analysis
revealed a higher immunoreactivity in the epithelium
from biopsies than polyps (area/length units: 94.3 ± 16.4
and 52.6 ± 6.7, respectively; 5 patients from each group;
Figure 4). In sections from 5 patients without and 6
patients with steroids, the treatment revealed a reduction
after the treatment (area/length units: 52.6 ± 6.7 and 27.5
± 8.1, respectively).
Discussion
In the present study mRNA expression of PPARα, PPARβδ,
PPARγ was found in all specimens. The expression of
PPARs between patients with allergic rhinitis and healthy
volunteers was more or less identical. Nasal polyps exhib-
ited lower mRNA expression levels of PPARα and PPARγ
than normal nasal mucosa and these levels were, for
PPARγ, further reduced following four weeks of treatment
with local steroids. PPARγ immunofluorescence was
prominent in the epithelium of both normal nasal
mucosa and polyps. The epithelial PPARγ immunoreactiv-
ity was similar in nasal biopsies from patients with allergic
rhinitis and healthy volunteers, but was lower in polyps
and further decreased after treatment with fluticasone.
In concordance with the present findings PPARγ has been
found to be expressed in cultured human epithelial cells
and its activation has been shown to antagonize pro-
inflammatory events in this system [25]. In monocytes
and macrophages PPARγ-agonists inhibit the expression
of proinflammatory cytokines, such as TNF-α, IL-1β, and
IL-6 [26,27]. PPARγ is also expressed by eosinophils and
agonists inhibit eosinophil chemotaxis and antibody-
dependent cellular cytotoxicity reactions in vitro [22].
Similar in vivo findings have been seen in a murine model
of asthma, where treatment with a PPARγ agonist inhib-
ited the development of allergic inflammation, including
pulmonary eosinophilia and airway hyperreactivity
[22,28]. Furthermore, it was recently demonstrated that
cultured human airway smooth muscle cells express
PPARα and PPARγ [29], which might relate to the present
finding of PPARγ positive cells in conjunction with the
vascular smooth muscle in biopsies from both the inferior
turbinate and polyps.
Based on animal studies and in vitro data, an anti-inflam-
matory role for PPARγ has been suggested. However,
human data to support this idea are still limited. Benay-
oun and colleagues have shown that PPARγ is augmented
in the bronchial submucosa, the airway epithelium, and
the smooth muscle of asthmatic patients, as compared
with control subjects [24]. The enhanced PPARγ expres-
sion is accompanied by increased proliferation and apop-
tosis of airway epithelial and submucosal cells. In
addition, several studies have demonstrated that PPARγ
plays an important role in the control of the inflammatory
response [21,30], acting on T cells, macrophages, den-
dritic cells, and mast cells [31-34]. Therefore, an increased
expression of PPARγ could have been expected in con-
junction with the increased amount of inflammatory cells
seen during symptomatic allergic rhinitis. This alteration
could not be found in the present study. Since PPARγ
appears to be expressed in response to the ongoing
inflammation, it might be that it takes more than 3–4
days of pollen exposure to fully activate this putative
"defense system".
Nasal polyposis represents a chronic type of inflamma-
tion and the lower levels of PPARγ in comparison with
normal nasal mucosa might reflect a reduced ability of the
diseased mucosa to respond to airway inflammation,
thereby facilitating the polyp formation. Steroids (locally
administrated, with or without an oral supplement) have,
in analogy with our experiments, been reported to down
regulate PPARγ expression in bronchial epithelium,
mucosa and smooth muscle [24]. Thus, the beneficial
effect of glucocorticoid treatment on nasal polyposis may
adversely affect the down-regulation of PPARγ. On the
other hand, if the inflammatory response is reduced, there
will be less need for anti-inflammatory mediators. Not-
withstanding whether this is beneficial or not, these stud-
Expression levels of PPARα, PPARβδ and PPARγ in polyps from 7 patients with bilateral nasal polyposis before (c ntrol) and after steroid treatmentFigure 2
Expression levels of PPARα, PPARβδ and PPARγ in polyps 
from 7 patients with bilateral nasal polyposis before (control) 
and after steroid treatment. Levels of PPAR mRNA are cal-
culated in relation to 100,000 mRNA molecules of β-actin. 
Bold lines represent the median values. The PPARγ levels 
were reduced following steroid treatment (*p < 0.05).Page 5 of 8
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therapy and that increased knowledge of the physiological
effect of PPARγ within the airways might be of importance
for our understanding of airway regulation
Neither PPARα nor βδ exhibited any difference in their
expression when specimens from healthy volunteers were
compared with samples obtained from patients with
symptomatic allergic rhinitis. Nor did local steroid treat-
ment affect the expression of these PPARs in nasal polypo-
sis. Inflammation induced by LTB4, a PPARα ligand, has
been shown to be prolonged in PPARα-deficient mice
[15], suggesting an anti-inflammatory role for this recep-
tor. In contrast, in mice injected with lipopolysaccharide
(LPS), activation of PPARα induced a significant increase
in plasma tumour necrosis factor-α (TNFα) levels [35].
Pro-differentiation and anti-proliferative effects in con-
junction with PPARα-stimulation have been demon-
strated in various skin models, as well as an ability for this
type of stimulation to reduce cutaneus inflammation in
vivo [36,37]. Albeit the lower expression of PPARα in pol-
yps, the present study did not give any further evidence for
a role for PPARα in airway inflammation. For PPARβδ,
which is ubiquitously expressed in the human body, the
eventual function in inflammation remains uncertain.
The relatively low expression level and the unaltered
expression seen in the present study add no further infor-
mation.
The present polyp data could be interpreted as a support
for the widespread idea of an anti-inflammatory role for
PPARγ within the human airways. However, data contra-
dicting an anti-inflammatory role for PPARγ has been
published [38,39]. This discrepancy has been attributed to
the use of nonselective ligands [38] or the use of very high
concentrations of more selective ligands [39]. In this con-
text, it is essential to recognize that inflammation is nor-
mally a self-resolving process with the existence of both
positive and negative regulators that ultimately allow
complete resolution and homeostasis. In the absence of
resolution and clearance or in the event of a dampened
healing response, persistent inflammation can arise in the
form of tissue damage as associated with chronic disease.
The down-regulation of PPARγ, in nasal polyposis but not
in turbinates during symptomatic seasonal rhinitis, sug-
gests that PPARγ might be of importance in long standing
inflammations, causing polyps, whereas an eventual role
in allergic rhinitis remains to be established. It is tempting
to speculate in a therapeutic future for PPARγ activating
agonists in the treatment of long standing airway inflam-
mation.
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